nodes	percent_of_prediction	percent_of_DWPC	metapath
Droxidopa—L-DOPA—Melphalan—peripheral nervous system neoplasm	0.829	1	CrCrCtD
Droxidopa—Cardiac failure congestive—Tretinoin—peripheral nervous system neoplasm	0.0014	0.0375	CcSEcCtD
Droxidopa—Cardiac failure congestive—Isotretinoin—peripheral nervous system neoplasm	0.0014	0.0375	CcSEcCtD
Droxidopa—Cardiac failure congestive—Alitretinoin—peripheral nervous system neoplasm	0.00106	0.0284	CcSEcCtD
Droxidopa—Urinary tract infection—Tretinoin—peripheral nervous system neoplasm	0.000949	0.0255	CcSEcCtD
Droxidopa—Urinary tract infection—Isotretinoin—peripheral nervous system neoplasm	0.000949	0.0255	CcSEcCtD
Droxidopa—Cardiac failure congestive—Cisplatin—peripheral nervous system neoplasm	0.000902	0.0242	CcSEcCtD
Droxidopa—Cardiac failure congestive—Etoposide—peripheral nervous system neoplasm	0.000827	0.0222	CcSEcCtD
Droxidopa—Arrhythmia—Isotretinoin—peripheral nervous system neoplasm	0.000783	0.021	CcSEcCtD
Droxidopa—Arrhythmia—Tretinoin—peripheral nervous system neoplasm	0.000783	0.021	CcSEcCtD
Droxidopa—Arrhythmia—Melphalan—peripheral nervous system neoplasm	0.000773	0.0207	CcSEcCtD
Droxidopa—Urinary tract infection—Alitretinoin—peripheral nervous system neoplasm	0.000719	0.0193	CcSEcCtD
Droxidopa—Syncope—Tretinoin—peripheral nervous system neoplasm	0.000684	0.0184	CcSEcCtD
Droxidopa—Syncope—Isotretinoin—peripheral nervous system neoplasm	0.000684	0.0184	CcSEcCtD
Droxidopa—Loss of consciousness—Isotretinoin—peripheral nervous system neoplasm	0.000671	0.018	CcSEcCtD
Droxidopa—Loss of consciousness—Tretinoin—peripheral nervous system neoplasm	0.000671	0.018	CcSEcCtD
Droxidopa—Hypertension—Tretinoin—peripheral nervous system neoplasm	0.000659	0.0177	CcSEcCtD
Droxidopa—Hypertension—Isotretinoin—peripheral nervous system neoplasm	0.000659	0.0177	CcSEcCtD
Droxidopa—Confusional state—Tretinoin—peripheral nervous system neoplasm	0.000628	0.0169	CcSEcCtD
Droxidopa—Confusional state—Isotretinoin—peripheral nervous system neoplasm	0.000628	0.0169	CcSEcCtD
Droxidopa—Shock—Tretinoin—peripheral nervous system neoplasm	0.000613	0.0164	CcSEcCtD
Droxidopa—Shock—Isotretinoin—peripheral nervous system neoplasm	0.000613	0.0164	CcSEcCtD
Droxidopa—Arrhythmia—Alitretinoin—peripheral nervous system neoplasm	0.000593	0.0159	CcSEcCtD
Droxidopa—Syncope—Alitretinoin—peripheral nervous system neoplasm	0.000519	0.0139	CcSEcCtD
Droxidopa—Feeling abnormal—Topotecan—peripheral nervous system neoplasm	0.000517	0.0139	CcSEcCtD
Droxidopa—Feeling abnormal—Tretinoin—peripheral nervous system neoplasm	0.000513	0.0138	CcSEcCtD
Droxidopa—Feeling abnormal—Isotretinoin—peripheral nervous system neoplasm	0.000513	0.0138	CcSEcCtD
Droxidopa—Loss of consciousness—Alitretinoin—peripheral nervous system neoplasm	0.000508	0.0136	CcSEcCtD
Droxidopa—Arrhythmia—Cisplatin—peripheral nervous system neoplasm	0.000506	0.0136	CcSEcCtD
Droxidopa—Hypertension—Alitretinoin—peripheral nervous system neoplasm	0.000499	0.0134	CcSEcCtD
Droxidopa—Hypertension—Vincristine—peripheral nervous system neoplasm	0.000481	0.0129	CcSEcCtD
Droxidopa—Confusional state—Alitretinoin—peripheral nervous system neoplasm	0.000476	0.0128	CcSEcCtD
Droxidopa—Shock—Alitretinoin—peripheral nervous system neoplasm	0.000464	0.0125	CcSEcCtD
Droxidopa—Cardiac failure congestive—Epirubicin—peripheral nervous system neoplasm	0.000463	0.0124	CcSEcCtD
Droxidopa—Cardiac failure congestive—Doxorubicin—peripheral nervous system neoplasm	0.000429	0.0115	CcSEcCtD
Droxidopa—Feeling abnormal—Dactinomycin—peripheral nervous system neoplasm	0.000419	0.0113	CcSEcCtD
Droxidopa—Dizziness—Topotecan—peripheral nervous system neoplasm	0.000415	0.0111	CcSEcCtD
Droxidopa—Dizziness—Tretinoin—peripheral nervous system neoplasm	0.000412	0.0111	CcSEcCtD
Droxidopa—Dizziness—Isotretinoin—peripheral nervous system neoplasm	0.000412	0.0111	CcSEcCtD
Droxidopa—Loss of consciousness—Etoposide—peripheral nervous system neoplasm	0.000397	0.0106	CcSEcCtD
Droxidopa—Headache—Topotecan—peripheral nervous system neoplasm	0.000393	0.0106	CcSEcCtD
Droxidopa—Headache—Tretinoin—peripheral nervous system neoplasm	0.00039	0.0105	CcSEcCtD
Droxidopa—Headache—Isotretinoin—peripheral nervous system neoplasm	0.00039	0.0105	CcSEcCtD
Droxidopa—Hypertension—Etoposide—peripheral nervous system neoplasm	0.00039	0.0105	CcSEcCtD
Droxidopa—Feeling abnormal—Alitretinoin—peripheral nervous system neoplasm	0.000389	0.0104	CcSEcCtD
Droxidopa—Nausea—Topotecan—peripheral nervous system neoplasm	0.000373	0.01	CcSEcCtD
Droxidopa—Confusional state—Etoposide—peripheral nervous system neoplasm	0.000371	0.00997	CcSEcCtD
Droxidopa—Nausea—Isotretinoin—peripheral nervous system neoplasm	0.00037	0.00993	CcSEcCtD
Droxidopa—Nausea—Tretinoin—peripheral nervous system neoplasm	0.00037	0.00993	CcSEcCtD
Droxidopa—Nausea—Melphalan—peripheral nervous system neoplasm	0.000365	0.0098	CcSEcCtD
Droxidopa—Feeling abnormal—Cisplatin—peripheral nervous system neoplasm	0.000331	0.00889	CcSEcCtD
Droxidopa—Urinary tract infection—Epirubicin—peripheral nervous system neoplasm	0.000315	0.00845	CcSEcCtD
Droxidopa—Dizziness—Alitretinoin—peripheral nervous system neoplasm	0.000312	0.00838	CcSEcCtD
Droxidopa—Feeling abnormal—Etoposide—peripheral nervous system neoplasm	0.000304	0.00815	CcSEcCtD
Droxidopa—Nausea—Dactinomycin—peripheral nervous system neoplasm	0.000302	0.00812	CcSEcCtD
Droxidopa—Dizziness—Vincristine—peripheral nervous system neoplasm	0.000301	0.00807	CcSEcCtD
Droxidopa—Headache—Alitretinoin—peripheral nervous system neoplasm	0.000296	0.00794	CcSEcCtD
Droxidopa—Urinary tract infection—Doxorubicin—peripheral nervous system neoplasm	0.000291	0.00782	CcSEcCtD
Droxidopa—Headache—Vincristine—peripheral nervous system neoplasm	0.000285	0.00765	CcSEcCtD
Droxidopa—Nausea—Alitretinoin—peripheral nervous system neoplasm	0.00028	0.00752	CcSEcCtD
Droxidopa—Nausea—Vincristine—peripheral nervous system neoplasm	0.00027	0.00725	CcSEcCtD
Droxidopa—Arrhythmia—Epirubicin—peripheral nervous system neoplasm	0.00026	0.00697	CcSEcCtD
Droxidopa—Dizziness—Etoposide—peripheral nervous system neoplasm	0.000244	0.00654	CcSEcCtD
Droxidopa—Arrhythmia—Doxorubicin—peripheral nervous system neoplasm	0.00024	0.00645	CcSEcCtD
Droxidopa—Nausea—Cisplatin—peripheral nervous system neoplasm	0.000239	0.00641	CcSEcCtD
Droxidopa—Headache—Etoposide—peripheral nervous system neoplasm	0.000231	0.00619	CcSEcCtD
Droxidopa—Syncope—Epirubicin—peripheral nervous system neoplasm	0.000227	0.00609	CcSEcCtD
Droxidopa—Loss of consciousness—Epirubicin—peripheral nervous system neoplasm	0.000222	0.00597	CcSEcCtD
Droxidopa—Nausea—Etoposide—peripheral nervous system neoplasm	0.000219	0.00587	CcSEcCtD
Droxidopa—Hypertension—Epirubicin—peripheral nervous system neoplasm	0.000218	0.00586	CcSEcCtD
Droxidopa—Syncope—Doxorubicin—peripheral nervous system neoplasm	0.00021	0.00564	CcSEcCtD
Droxidopa—Confusional state—Epirubicin—peripheral nervous system neoplasm	0.000208	0.00559	CcSEcCtD
Droxidopa—Loss of consciousness—Doxorubicin—peripheral nervous system neoplasm	0.000206	0.00552	CcSEcCtD
Droxidopa—Shock—Epirubicin—peripheral nervous system neoplasm	0.000203	0.00545	CcSEcCtD
Droxidopa—Hypertension—Doxorubicin—peripheral nervous system neoplasm	0.000202	0.00543	CcSEcCtD
Droxidopa—Confusional state—Doxorubicin—peripheral nervous system neoplasm	0.000193	0.00517	CcSEcCtD
Droxidopa—Shock—Doxorubicin—peripheral nervous system neoplasm	0.000188	0.00505	CcSEcCtD
Droxidopa—Feeling abnormal—Epirubicin—peripheral nervous system neoplasm	0.00017	0.00457	CcSEcCtD
Droxidopa—Feeling abnormal—Doxorubicin—peripheral nervous system neoplasm	0.000157	0.00423	CcSEcCtD
Droxidopa—Dizziness—Epirubicin—peripheral nervous system neoplasm	0.000137	0.00367	CcSEcCtD
Droxidopa—Headache—Epirubicin—peripheral nervous system neoplasm	0.000129	0.00347	CcSEcCtD
Droxidopa—Dizziness—Doxorubicin—peripheral nervous system neoplasm	0.000126	0.00339	CcSEcCtD
Droxidopa—Nausea—Epirubicin—peripheral nervous system neoplasm	0.000123	0.00329	CcSEcCtD
Droxidopa—Headache—Doxorubicin—peripheral nervous system neoplasm	0.00012	0.00321	CcSEcCtD
Droxidopa—Nausea—Doxorubicin—peripheral nervous system neoplasm	0.000113	0.00305	CcSEcCtD
Droxidopa—ADRA1B—Signaling Pathways—CD55—peripheral nervous system neoplasm	7.08e-05	0.000528	CbGpPWpGaD
Droxidopa—ADRA2A—Hemostasis—GNAS—peripheral nervous system neoplasm	7.07e-05	0.000527	CbGpPWpGaD
Droxidopa—ADRA2A—Metabolism—NME1—peripheral nervous system neoplasm	6.99e-05	0.000521	CbGpPWpGaD
Droxidopa—ADRB1—GPCR downstream signaling—KNG1—peripheral nervous system neoplasm	6.79e-05	0.000506	CbGpPWpGaD
Droxidopa—ADRA1D—Signaling by GPCR—KNG1—peripheral nervous system neoplasm	6.77e-05	0.000505	CbGpPWpGaD
Droxidopa—ADRA1D—Signaling Pathways—VIP—peripheral nervous system neoplasm	6.75e-05	0.000503	CbGpPWpGaD
Droxidopa—ADRA2A—Hemostasis—HGF—peripheral nervous system neoplasm	6.73e-05	0.000502	CbGpPWpGaD
Droxidopa—ADRA2B—GPCR downstream signaling—KNG1—peripheral nervous system neoplasm	6.73e-05	0.000502	CbGpPWpGaD
Droxidopa—ADRA2A—Metabolism—COX2—peripheral nervous system neoplasm	6.73e-05	0.000502	CbGpPWpGaD
Droxidopa—ADRB2—GPCR downstream signaling—KNG1—peripheral nervous system neoplasm	6.65e-05	0.000495	CbGpPWpGaD
Droxidopa—ADRA1A—Signaling Pathways—NTS—peripheral nervous system neoplasm	6.56e-05	0.000489	CbGpPWpGaD
Droxidopa—ADRA1D—GPCR downstream signaling—GNAS—peripheral nervous system neoplasm	6.52e-05	0.000486	CbGpPWpGaD
Droxidopa—ADRA2B—Hemostasis—PTPN11—peripheral nervous system neoplasm	6.47e-05	0.000483	CbGpPWpGaD
Droxidopa—ADRB3—Signaling by GPCR—PTPN11—peripheral nervous system neoplasm	6.32e-05	0.000471	CbGpPWpGaD
Droxidopa—ADRA1A—Gastrin-CREB signalling pathway via PKC and MAPK—NRAS—peripheral nervous system neoplasm	6.3e-05	0.00047	CbGpPWpGaD
Droxidopa—ADRA1A—Signaling Pathways—CD55—peripheral nervous system neoplasm	6.29e-05	0.000469	CbGpPWpGaD
Droxidopa—ADRA2C—GPCR downstream signaling—KNG1—peripheral nervous system neoplasm	6.29e-05	0.000469	CbGpPWpGaD
Droxidopa—PAH—Disease—NRAS—peripheral nervous system neoplasm	6.26e-05	0.000467	CbGpPWpGaD
Droxidopa—ADRA1D—Gastrin-CREB signalling pathway via PKC and MAPK—HRAS—peripheral nervous system neoplasm	6.26e-05	0.000466	CbGpPWpGaD
Droxidopa—ADRA1D—Signaling Pathways—PPP3R1—peripheral nervous system neoplasm	6.23e-05	0.000464	CbGpPWpGaD
Droxidopa—ADRA1B—GPCR downstream signaling—KNG1—peripheral nervous system neoplasm	6.19e-05	0.000461	CbGpPWpGaD
Droxidopa—ADRB1—Signaling by GPCR—KNG1—peripheral nervous system neoplasm	6.17e-05	0.00046	CbGpPWpGaD
Droxidopa—ADRB1—Signaling Pathways—VIP—peripheral nervous system neoplasm	6.15e-05	0.000458	CbGpPWpGaD
Droxidopa—ADRB3—Signaling Pathways—KNG1—peripheral nervous system neoplasm	6.14e-05	0.000458	CbGpPWpGaD
Droxidopa—ADRA2B—Signaling by GPCR—KNG1—peripheral nervous system neoplasm	6.11e-05	0.000456	CbGpPWpGaD
Droxidopa—ADRA2A—Signaling Pathways—NTS—peripheral nervous system neoplasm	6.1e-05	0.000455	CbGpPWpGaD
Droxidopa—ADRA2B—Signaling Pathways—VIP—peripheral nervous system neoplasm	6.09e-05	0.000454	CbGpPWpGaD
Droxidopa—ADRA2C—Hemostasis—PTPN11—peripheral nervous system neoplasm	6.05e-05	0.000451	CbGpPWpGaD
Droxidopa—ADRB2—Signaling by GPCR—KNG1—peripheral nervous system neoplasm	6.04e-05	0.00045	CbGpPWpGaD
Droxidopa—ADRB2—Signaling Pathways—VIP—peripheral nervous system neoplasm	6.01e-05	0.000448	CbGpPWpGaD
Droxidopa—ADRB1—GPCR downstream signaling—GNAS—peripheral nervous system neoplasm	5.94e-05	0.000443	CbGpPWpGaD
Droxidopa—ADRA1D—Signaling by GPCR—GNAS—peripheral nervous system neoplasm	5.92e-05	0.000441	CbGpPWpGaD
Droxidopa—ADRA2B—GPCR downstream signaling—GNAS—peripheral nervous system neoplasm	5.89e-05	0.000439	CbGpPWpGaD
Droxidopa—ADRB3—Signaling Pathways—NTRK1—peripheral nervous system neoplasm	5.85e-05	0.000436	CbGpPWpGaD
Droxidopa—ADRA2A—Signaling Pathways—CD55—peripheral nervous system neoplasm	5.85e-05	0.000436	CbGpPWpGaD
Droxidopa—PAH—Disease—MYC—peripheral nervous system neoplasm	5.83e-05	0.000435	CbGpPWpGaD
Droxidopa—ADRB2—GPCR downstream signaling—GNAS—peripheral nervous system neoplasm	5.81e-05	0.000433	CbGpPWpGaD
Droxidopa—ADRA2C—Signaling by GPCR—KNG1—peripheral nervous system neoplasm	5.71e-05	0.000426	CbGpPWpGaD
Droxidopa—ADRA2C—Signaling Pathways—VIP—peripheral nervous system neoplasm	5.69e-05	0.000424	CbGpPWpGaD
Droxidopa—ADRB1—Signaling Pathways—PPP3R1—peripheral nervous system neoplasm	5.67e-05	0.000423	CbGpPWpGaD
Droxidopa—ADRA2B—Signaling Pathways—PPP3R1—peripheral nervous system neoplasm	5.62e-05	0.000419	CbGpPWpGaD
Droxidopa—ADRA1B—Signaling by GPCR—KNG1—peripheral nervous system neoplasm	5.62e-05	0.000419	CbGpPWpGaD
Droxidopa—ADRA1B—Signaling Pathways—VIP—peripheral nervous system neoplasm	5.6e-05	0.000417	CbGpPWpGaD
Droxidopa—ADRB2—Signaling Pathways—PPP3R1—peripheral nervous system neoplasm	5.55e-05	0.000414	CbGpPWpGaD
Droxidopa—ADRA2C—GPCR downstream signaling—GNAS—peripheral nervous system neoplasm	5.5e-05	0.00041	CbGpPWpGaD
Droxidopa—ADRA1A—GPCR downstream signaling—KNG1—peripheral nervous system neoplasm	5.5e-05	0.00041	CbGpPWpGaD
Droxidopa—ADRA2C—Metabolism—ENO2—peripheral nervous system neoplasm	5.44e-05	0.000405	CbGpPWpGaD
Droxidopa—ADRA1B—GPCR downstream signaling—GNAS—peripheral nervous system neoplasm	5.41e-05	0.000403	CbGpPWpGaD
Droxidopa—ADRB1—Signaling by GPCR—GNAS—peripheral nervous system neoplasm	5.4e-05	0.000402	CbGpPWpGaD
Droxidopa—ADRB3—Signaling Pathways—GNAS—peripheral nervous system neoplasm	5.37e-05	0.0004	CbGpPWpGaD
Droxidopa—ADRA2B—Signaling by GPCR—GNAS—peripheral nervous system neoplasm	5.35e-05	0.000398	CbGpPWpGaD
Droxidopa—ADRB2—Signaling by GPCR—GNAS—peripheral nervous system neoplasm	5.28e-05	0.000393	CbGpPWpGaD
Droxidopa—ADRA2C—Signaling Pathways—PPP3R1—peripheral nervous system neoplasm	5.25e-05	0.000391	CbGpPWpGaD
Droxidopa—ADRA1B—Gastrin-CREB signalling pathway via PKC and MAPK—HRAS—peripheral nervous system neoplasm	5.19e-05	0.000387	CbGpPWpGaD
Droxidopa—ADRA1B—Signaling Pathways—PPP3R1—peripheral nervous system neoplasm	5.17e-05	0.000385	CbGpPWpGaD
Droxidopa—ADRA2A—GPCR downstream signaling—KNG1—peripheral nervous system neoplasm	5.11e-05	0.000381	CbGpPWpGaD
Droxidopa—ADRA2C—Signaling by GPCR—GNAS—peripheral nervous system neoplasm	4.99e-05	0.000372	CbGpPWpGaD
Droxidopa—ADRA1A—Signaling by GPCR—KNG1—peripheral nervous system neoplasm	4.99e-05	0.000372	CbGpPWpGaD
Droxidopa—ADRA1A—Signaling Pathways—VIP—peripheral nervous system neoplasm	4.97e-05	0.000371	CbGpPWpGaD
Droxidopa—ADRA1B—Signaling by GPCR—GNAS—peripheral nervous system neoplasm	4.91e-05	0.000366	CbGpPWpGaD
Droxidopa—ADRA2A—Hemostasis—PTPN11—peripheral nervous system neoplasm	4.91e-05	0.000366	CbGpPWpGaD
Droxidopa—ADRA2B—Platelet activation, signaling and aggregation—AKT1—peripheral nervous system neoplasm	4.88e-05	0.000364	CbGpPWpGaD
Droxidopa—ADRA1A—GPCR downstream signaling—GNAS—peripheral nervous system neoplasm	4.81e-05	0.000358	CbGpPWpGaD
Droxidopa—ADRA1D—Signaling Pathways—NTRK2—peripheral nervous system neoplasm	4.68e-05	0.000349	CbGpPWpGaD
Droxidopa—ADRA2A—Signaling by GPCR—KNG1—peripheral nervous system neoplasm	4.64e-05	0.000346	CbGpPWpGaD
Droxidopa—ADRA2A—Signaling Pathways—VIP—peripheral nervous system neoplasm	4.62e-05	0.000344	CbGpPWpGaD
Droxidopa—ADRA1A—Gastrin-CREB signalling pathway via PKC and MAPK—HRAS—peripheral nervous system neoplasm	4.61e-05	0.000344	CbGpPWpGaD
Droxidopa—ADRA2C—Metabolism—BCHE—peripheral nervous system neoplasm	4.6e-05	0.000343	CbGpPWpGaD
Droxidopa—ADRA1A—Signaling Pathways—PPP3R1—peripheral nervous system neoplasm	4.59e-05	0.000342	CbGpPWpGaD
Droxidopa—PAH—Disease—HRAS—peripheral nervous system neoplasm	4.58e-05	0.000342	CbGpPWpGaD
Droxidopa—ADRA2C—Platelet activation, signaling and aggregation—AKT1—peripheral nervous system neoplasm	4.56e-05	0.00034	CbGpPWpGaD
Droxidopa—ADRA2A—GPCR downstream signaling—GNAS—peripheral nervous system neoplasm	4.47e-05	0.000333	CbGpPWpGaD
Droxidopa—ADRA2A—Metabolism—ENO2—peripheral nervous system neoplasm	4.42e-05	0.000329	CbGpPWpGaD
Droxidopa—ADRA2C—Metabolism—SLC2A1—peripheral nervous system neoplasm	4.39e-05	0.000327	CbGpPWpGaD
Droxidopa—ADRA1A—Signaling by GPCR—GNAS—peripheral nervous system neoplasm	4.37e-05	0.000325	CbGpPWpGaD
Droxidopa—ADRA2C—Metabolism—TH—peripheral nervous system neoplasm	4.32e-05	0.000322	CbGpPWpGaD
Droxidopa—ADRA2A—Signaling Pathways—PPP3R1—peripheral nervous system neoplasm	4.27e-05	0.000318	CbGpPWpGaD
Droxidopa—ADRB1—Signaling Pathways—NTRK2—peripheral nervous system neoplasm	4.26e-05	0.000318	CbGpPWpGaD
Droxidopa—ADRA2B—Signaling Pathways—NTRK2—peripheral nervous system neoplasm	4.22e-05	0.000315	CbGpPWpGaD
Droxidopa—ADRB2—Signaling Pathways—NTRK2—peripheral nervous system neoplasm	4.17e-05	0.000311	CbGpPWpGaD
Droxidopa—ADRA1D—Signaling by GPCR—PTPN11—peripheral nervous system neoplasm	4.12e-05	0.000307	CbGpPWpGaD
Droxidopa—ADRA2A—Signaling by GPCR—GNAS—peripheral nervous system neoplasm	4.06e-05	0.000302	CbGpPWpGaD
Droxidopa—PAH—Disease—AKT1—peripheral nervous system neoplasm	4.05e-05	0.000302	CbGpPWpGaD
Droxidopa—ADRA1D—Signaling Pathways—KNG1—peripheral nervous system neoplasm	4e-05	0.000298	CbGpPWpGaD
Droxidopa—ADRA2C—Signaling Pathways—NTRK2—peripheral nervous system neoplasm	3.94e-05	0.000294	CbGpPWpGaD
Droxidopa—ADRA2B—Hemostasis—NRAS—peripheral nervous system neoplasm	3.89e-05	0.00029	CbGpPWpGaD
Droxidopa—ADRA1B—Signaling Pathways—NTRK2—peripheral nervous system neoplasm	3.88e-05	0.000289	CbGpPWpGaD
Droxidopa—ADRA1D—Signaling Pathways—NTRK1—peripheral nervous system neoplasm	3.81e-05	0.000284	CbGpPWpGaD
Droxidopa—ADRB3—Signaling by GPCR—NRAS—peripheral nervous system neoplasm	3.8e-05	0.000283	CbGpPWpGaD
Droxidopa—ADRB1—Signaling by GPCR—PTPN11—peripheral nervous system neoplasm	3.75e-05	0.000279	CbGpPWpGaD
Droxidopa—ADRA2A—Metabolism—BCHE—peripheral nervous system neoplasm	3.73e-05	0.000278	CbGpPWpGaD
Droxidopa—ADRB3—Signaling Pathways—PTPN11—peripheral nervous system neoplasm	3.73e-05	0.000278	CbGpPWpGaD
Droxidopa—ADRA2B—Signaling by GPCR—PTPN11—peripheral nervous system neoplasm	3.72e-05	0.000277	CbGpPWpGaD
Droxidopa—ADRA2A—Platelet activation, signaling and aggregation—AKT1—peripheral nervous system neoplasm	3.7e-05	0.000276	CbGpPWpGaD
Droxidopa—ADRB2—Signaling by GPCR—PTPN11—peripheral nervous system neoplasm	3.67e-05	0.000273	CbGpPWpGaD
Droxidopa—ADRB1—Signaling Pathways—KNG1—peripheral nervous system neoplasm	3.64e-05	0.000272	CbGpPWpGaD
Droxidopa—ADRA2C—Hemostasis—NRAS—peripheral nervous system neoplasm	3.64e-05	0.000271	CbGpPWpGaD
Droxidopa—ADRA2B—Signaling Pathways—KNG1—peripheral nervous system neoplasm	3.61e-05	0.000269	CbGpPWpGaD
Droxidopa—ADRB2—Signaling Pathways—KNG1—peripheral nervous system neoplasm	3.57e-05	0.000266	CbGpPWpGaD
Droxidopa—ADRA2A—Metabolism—SLC2A1—peripheral nervous system neoplasm	3.56e-05	0.000265	CbGpPWpGaD
Droxidopa—ADRA2C—Metabolism—GNAS—peripheral nervous system neoplasm	3.53e-05	0.000263	CbGpPWpGaD
Droxidopa—ADRA2A—Metabolism—TH—peripheral nervous system neoplasm	3.51e-05	0.000262	CbGpPWpGaD
Droxidopa—ADRA1D—Signaling Pathways—GNAS—peripheral nervous system neoplasm	3.5e-05	0.000261	CbGpPWpGaD
Droxidopa—ADRB1—Signaling Pathways—NTRK1—peripheral nervous system neoplasm	3.47e-05	0.000259	CbGpPWpGaD
Droxidopa—ADRA2C—Signaling by GPCR—PTPN11—peripheral nervous system neoplasm	3.47e-05	0.000259	CbGpPWpGaD
Droxidopa—ADRA2C—Metabolism—ABCB1—peripheral nervous system neoplasm	3.46e-05	0.000258	CbGpPWpGaD
Droxidopa—ADRA1A—Signaling Pathways—NTRK2—peripheral nervous system neoplasm	3.45e-05	0.000257	CbGpPWpGaD
Droxidopa—ADRA2B—Signaling Pathways—NTRK1—peripheral nervous system neoplasm	3.44e-05	0.000257	CbGpPWpGaD
Droxidopa—ADRA1B—Signaling by GPCR—PTPN11—peripheral nervous system neoplasm	3.42e-05	0.000255	CbGpPWpGaD
Droxidopa—ADRB2—Signaling Pathways—NTRK1—peripheral nervous system neoplasm	3.4e-05	0.000253	CbGpPWpGaD
Droxidopa—PAH—Metabolism—AKT1—peripheral nervous system neoplasm	3.39e-05	0.000253	CbGpPWpGaD
Droxidopa—ADRA2C—Signaling Pathways—KNG1—peripheral nervous system neoplasm	3.37e-05	0.000251	CbGpPWpGaD
Droxidopa—ADRA1B—Signaling Pathways—KNG1—peripheral nervous system neoplasm	3.32e-05	0.000247	CbGpPWpGaD
Droxidopa—ADRA2C—Signaling Pathways—NTRK1—peripheral nervous system neoplasm	3.22e-05	0.00024	CbGpPWpGaD
Droxidopa—ADRA2A—Signaling Pathways—NTRK2—peripheral nervous system neoplasm	3.2e-05	0.000239	CbGpPWpGaD
Droxidopa—ADRB1—Signaling Pathways—GNAS—peripheral nervous system neoplasm	3.19e-05	0.000238	CbGpPWpGaD
Droxidopa—ADRA1B—Signaling Pathways—NTRK1—peripheral nervous system neoplasm	3.16e-05	0.000236	CbGpPWpGaD
Droxidopa—ADRA2B—Signaling Pathways—GNAS—peripheral nervous system neoplasm	3.16e-05	0.000235	CbGpPWpGaD
Droxidopa—ADRB2—Signaling Pathways—GNAS—peripheral nervous system neoplasm	3.12e-05	0.000232	CbGpPWpGaD
Droxidopa—ADRA1A—Signaling by GPCR—PTPN11—peripheral nervous system neoplasm	3.03e-05	0.000226	CbGpPWpGaD
Droxidopa—ADRA2B—Hemostasis—TP53—peripheral nervous system neoplasm	2.98e-05	0.000222	CbGpPWpGaD
Droxidopa—ADRA2A—Hemostasis—NRAS—peripheral nervous system neoplasm	2.95e-05	0.00022	CbGpPWpGaD
Droxidopa—ADRA2C—Signaling Pathways—GNAS—peripheral nervous system neoplasm	2.95e-05	0.00022	CbGpPWpGaD
Droxidopa—ADRB3—Signaling Pathways—ERBB2—peripheral nervous system neoplasm	2.95e-05	0.00022	CbGpPWpGaD
Droxidopa—ADRA1A—Signaling Pathways—KNG1—peripheral nervous system neoplasm	2.95e-05	0.00022	CbGpPWpGaD
Droxidopa—ADRA1B—Signaling Pathways—GNAS—peripheral nervous system neoplasm	2.9e-05	0.000216	CbGpPWpGaD
Droxidopa—ADRA2A—Metabolism—GNAS—peripheral nervous system neoplasm	2.87e-05	0.000214	CbGpPWpGaD
Droxidopa—ADRA2B—Hemostasis—HRAS—peripheral nervous system neoplasm	2.85e-05	0.000212	CbGpPWpGaD
Droxidopa—ADRA2A—Signaling by GPCR—PTPN11—peripheral nervous system neoplasm	2.82e-05	0.00021	CbGpPWpGaD
Droxidopa—ADRA2A—Metabolism—ABCB1—peripheral nervous system neoplasm	2.81e-05	0.00021	CbGpPWpGaD
Droxidopa—ADRA1A—Signaling Pathways—NTRK1—peripheral nervous system neoplasm	2.81e-05	0.000209	CbGpPWpGaD
Droxidopa—ADRA2C—Hemostasis—TP53—peripheral nervous system neoplasm	2.78e-05	0.000207	CbGpPWpGaD
Droxidopa—ADRB3—Signaling by GPCR—HRAS—peripheral nervous system neoplasm	2.78e-05	0.000207	CbGpPWpGaD
Droxidopa—ADRA2A—Signaling Pathways—KNG1—peripheral nervous system neoplasm	2.74e-05	0.000204	CbGpPWpGaD
Droxidopa—ADRB3—GPCR downstream signaling—AKT1—peripheral nervous system neoplasm	2.7e-05	0.000201	CbGpPWpGaD
Droxidopa—ADRB3—Signaling Pathways—CASP3—peripheral nervous system neoplasm	2.68e-05	0.0002	CbGpPWpGaD
Droxidopa—ADRA2C—Hemostasis—HRAS—peripheral nervous system neoplasm	2.66e-05	0.000198	CbGpPWpGaD
Droxidopa—ADRA2A—Signaling Pathways—NTRK1—peripheral nervous system neoplasm	2.61e-05	0.000195	CbGpPWpGaD
Droxidopa—ADRA1A—Signaling Pathways—GNAS—peripheral nervous system neoplasm	2.58e-05	0.000192	CbGpPWpGaD
Droxidopa—ADRA2B—Hemostasis—AKT1—peripheral nervous system neoplasm	2.51e-05	0.000187	CbGpPWpGaD
Droxidopa—ADRA1D—Signaling by GPCR—NRAS—peripheral nervous system neoplasm	2.47e-05	0.000184	CbGpPWpGaD
Droxidopa—ADRB3—Signaling by GPCR—AKT1—peripheral nervous system neoplasm	2.45e-05	0.000183	CbGpPWpGaD
Droxidopa—ADRA1D—Signaling Pathways—PTPN11—peripheral nervous system neoplasm	2.43e-05	0.000181	CbGpPWpGaD
Droxidopa—ADRA2A—Signaling Pathways—GNAS—peripheral nervous system neoplasm	2.4e-05	0.000179	CbGpPWpGaD
Droxidopa—ADRA2C—Hemostasis—AKT1—peripheral nervous system neoplasm	2.35e-05	0.000175	CbGpPWpGaD
Droxidopa—ADRA2A—Hemostasis—TP53—peripheral nervous system neoplasm	2.26e-05	0.000168	CbGpPWpGaD
Droxidopa—ADRB1—Signaling by GPCR—NRAS—peripheral nervous system neoplasm	2.25e-05	0.000168	CbGpPWpGaD
Droxidopa—ADRB3—Signaling Pathways—NRAS—peripheral nervous system neoplasm	2.24e-05	0.000167	CbGpPWpGaD
Droxidopa—ADRA2B—Signaling by GPCR—NRAS—peripheral nervous system neoplasm	2.23e-05	0.000167	CbGpPWpGaD
Droxidopa—ADRB1—Signaling Pathways—PTPN11—peripheral nervous system neoplasm	2.22e-05	0.000165	CbGpPWpGaD
Droxidopa—ADRB2—Signaling by GPCR—NRAS—peripheral nervous system neoplasm	2.21e-05	0.000164	CbGpPWpGaD
Droxidopa—ADRA2B—Signaling Pathways—PTPN11—peripheral nervous system neoplasm	2.19e-05	0.000164	CbGpPWpGaD
Droxidopa—DDC—Metabolism—AKT1—peripheral nervous system neoplasm	2.19e-05	0.000163	CbGpPWpGaD
Droxidopa—ADRB2—Signaling Pathways—PTPN11—peripheral nervous system neoplasm	2.17e-05	0.000162	CbGpPWpGaD
Droxidopa—ADRA2A—Hemostasis—HRAS—peripheral nervous system neoplasm	2.16e-05	0.000161	CbGpPWpGaD
Droxidopa—ADRB3—Signaling Pathways—MYC—peripheral nervous system neoplasm	2.09e-05	0.000156	CbGpPWpGaD
Droxidopa—ADRA2C—Signaling by GPCR—NRAS—peripheral nervous system neoplasm	2.09e-05	0.000156	CbGpPWpGaD
Droxidopa—ADRA1B—Signaling by GPCR—NRAS—peripheral nervous system neoplasm	2.05e-05	0.000153	CbGpPWpGaD
Droxidopa—ADRA2C—Signaling Pathways—PTPN11—peripheral nervous system neoplasm	2.05e-05	0.000153	CbGpPWpGaD
Droxidopa—ADRA1B—Signaling Pathways—PTPN11—peripheral nervous system neoplasm	2.02e-05	0.00015	CbGpPWpGaD
Droxidopa—ADRA1D—Signaling Pathways—ERBB2—peripheral nervous system neoplasm	1.92e-05	0.000143	CbGpPWpGaD
Droxidopa—ADRA2A—Hemostasis—AKT1—peripheral nervous system neoplasm	1.91e-05	0.000142	CbGpPWpGaD
Droxidopa—ADRA1A—Signaling by GPCR—NRAS—peripheral nervous system neoplasm	1.82e-05	0.000136	CbGpPWpGaD
Droxidopa—ADRA1D—Signaling by GPCR—HRAS—peripheral nervous system neoplasm	1.81e-05	0.000135	CbGpPWpGaD
Droxidopa—ADRA1A—Signaling Pathways—PTPN11—peripheral nervous system neoplasm	1.79e-05	0.000134	CbGpPWpGaD
Droxidopa—ADRA1D—GPCR downstream signaling—AKT1—peripheral nervous system neoplasm	1.76e-05	0.000131	CbGpPWpGaD
Droxidopa—ADRB1—Signaling Pathways—ERBB2—peripheral nervous system neoplasm	1.75e-05	0.00013	CbGpPWpGaD
Droxidopa—ADRA1D—Signaling Pathways—CASP3—peripheral nervous system neoplasm	1.74e-05	0.00013	CbGpPWpGaD
Droxidopa—ADRA2B—Signaling Pathways—ERBB2—peripheral nervous system neoplasm	1.73e-05	0.000129	CbGpPWpGaD
Droxidopa—ADRB3—Signaling Pathways—TP53—peripheral nervous system neoplasm	1.72e-05	0.000128	CbGpPWpGaD
Droxidopa—ADRB2—Signaling Pathways—ERBB2—peripheral nervous system neoplasm	1.71e-05	0.000128	CbGpPWpGaD
Droxidopa—ADRA2A—Signaling by GPCR—NRAS—peripheral nervous system neoplasm	1.69e-05	0.000126	CbGpPWpGaD
Droxidopa—ADRA2A—Signaling Pathways—PTPN11—peripheral nervous system neoplasm	1.67e-05	0.000124	CbGpPWpGaD
Droxidopa—ADRB1—Signaling by GPCR—HRAS—peripheral nervous system neoplasm	1.65e-05	0.000123	CbGpPWpGaD
Droxidopa—ADRB3—Signaling Pathways—HRAS—peripheral nervous system neoplasm	1.64e-05	0.000122	CbGpPWpGaD
Droxidopa—ADRA2B—Signaling by GPCR—HRAS—peripheral nervous system neoplasm	1.63e-05	0.000122	CbGpPWpGaD
Droxidopa—ADRA2C—Signaling Pathways—ERBB2—peripheral nervous system neoplasm	1.62e-05	0.000121	CbGpPWpGaD
Droxidopa—ADRB2—Signaling by GPCR—HRAS—peripheral nervous system neoplasm	1.61e-05	0.00012	CbGpPWpGaD
Droxidopa—ADRB1—GPCR downstream signaling—AKT1—peripheral nervous system neoplasm	1.6e-05	0.00012	CbGpPWpGaD
Droxidopa—ADRA1D—Signaling by GPCR—AKT1—peripheral nervous system neoplasm	1.6e-05	0.000119	CbGpPWpGaD
Droxidopa—ADRA1B—Signaling Pathways—ERBB2—peripheral nervous system neoplasm	1.59e-05	0.000119	CbGpPWpGaD
Droxidopa—ADRA2B—GPCR downstream signaling—AKT1—peripheral nervous system neoplasm	1.59e-05	0.000118	CbGpPWpGaD
Droxidopa—ADRB1—Signaling Pathways—CASP3—peripheral nervous system neoplasm	1.59e-05	0.000118	CbGpPWpGaD
Droxidopa—ADRA2B—Signaling Pathways—CASP3—peripheral nervous system neoplasm	1.57e-05	0.000117	CbGpPWpGaD
Droxidopa—ADRB2—GPCR downstream signaling—AKT1—peripheral nervous system neoplasm	1.57e-05	0.000117	CbGpPWpGaD
Droxidopa—ADRB2—Signaling Pathways—CASP3—peripheral nervous system neoplasm	1.55e-05	0.000116	CbGpPWpGaD
Droxidopa—ADRA2C—Signaling by GPCR—HRAS—peripheral nervous system neoplasm	1.53e-05	0.000114	CbGpPWpGaD
Droxidopa—ADRA1B—Signaling by GPCR—HRAS—peripheral nervous system neoplasm	1.5e-05	0.000112	CbGpPWpGaD
Droxidopa—ADRA2C—GPCR downstream signaling—AKT1—peripheral nervous system neoplasm	1.48e-05	0.000111	CbGpPWpGaD
Droxidopa—ADRA2C—Signaling Pathways—CASP3—peripheral nervous system neoplasm	1.47e-05	0.00011	CbGpPWpGaD
Droxidopa—ADRA1D—Signaling Pathways—NRAS—peripheral nervous system neoplasm	1.46e-05	0.000109	CbGpPWpGaD
Droxidopa—ADRA1B—GPCR downstream signaling—AKT1—peripheral nervous system neoplasm	1.46e-05	0.000109	CbGpPWpGaD
Droxidopa—ADRB1—Signaling by GPCR—AKT1—peripheral nervous system neoplasm	1.46e-05	0.000109	CbGpPWpGaD
Droxidopa—ADRB3—Signaling Pathways—AKT1—peripheral nervous system neoplasm	1.45e-05	0.000108	CbGpPWpGaD
Droxidopa—ADRA1B—Signaling Pathways—CASP3—peripheral nervous system neoplasm	1.45e-05	0.000108	CbGpPWpGaD
Droxidopa—ADRA2B—Signaling by GPCR—AKT1—peripheral nervous system neoplasm	1.44e-05	0.000108	CbGpPWpGaD
Droxidopa—ADRB2—Signaling by GPCR—AKT1—peripheral nervous system neoplasm	1.42e-05	0.000106	CbGpPWpGaD
Droxidopa—ADRA1A—Signaling Pathways—ERBB2—peripheral nervous system neoplasm	1.42e-05	0.000106	CbGpPWpGaD
Droxidopa—ADRA1D—Signaling Pathways—MYC—peripheral nervous system neoplasm	1.36e-05	0.000101	CbGpPWpGaD
Droxidopa—ADRA2C—Signaling by GPCR—AKT1—peripheral nervous system neoplasm	1.35e-05	0.0001	CbGpPWpGaD
Droxidopa—ADRA1A—Signaling by GPCR—HRAS—peripheral nervous system neoplasm	1.33e-05	9.95e-05	CbGpPWpGaD
Droxidopa—ADRB1—Signaling Pathways—NRAS—peripheral nervous system neoplasm	1.33e-05	9.93e-05	CbGpPWpGaD
Droxidopa—ADRA1B—Signaling by GPCR—AKT1—peripheral nervous system neoplasm	1.33e-05	9.89e-05	CbGpPWpGaD
Droxidopa—ADRA2B—Signaling Pathways—NRAS—peripheral nervous system neoplasm	1.32e-05	9.84e-05	CbGpPWpGaD
Droxidopa—ADRA2A—Signaling Pathways—ERBB2—peripheral nervous system neoplasm	1.32e-05	9.81e-05	CbGpPWpGaD
Droxidopa—ADRB2—Signaling Pathways—NRAS—peripheral nervous system neoplasm	1.3e-05	9.71e-05	CbGpPWpGaD
Droxidopa—ADRA1A—GPCR downstream signaling—AKT1—peripheral nervous system neoplasm	1.3e-05	9.67e-05	CbGpPWpGaD
Droxidopa—ADRA1A—Signaling Pathways—CASP3—peripheral nervous system neoplasm	1.29e-05	9.58e-05	CbGpPWpGaD
Droxidopa—ADRB1—Signaling Pathways—MYC—peripheral nervous system neoplasm	1.24e-05	9.25e-05	CbGpPWpGaD
Droxidopa—ADRA2A—Signaling by GPCR—HRAS—peripheral nervous system neoplasm	1.24e-05	9.24e-05	CbGpPWpGaD
Droxidopa—ADRA2C—Signaling Pathways—NRAS—peripheral nervous system neoplasm	1.23e-05	9.19e-05	CbGpPWpGaD
Droxidopa—ADRA2B—Signaling Pathways—MYC—peripheral nervous system neoplasm	1.23e-05	9.16e-05	CbGpPWpGaD
Droxidopa—ADRB2—Signaling Pathways—MYC—peripheral nervous system neoplasm	1.21e-05	9.05e-05	CbGpPWpGaD
Droxidopa—ADRA1B—Signaling Pathways—NRAS—peripheral nervous system neoplasm	1.21e-05	9.04e-05	CbGpPWpGaD
Droxidopa—ADRA2A—GPCR downstream signaling—AKT1—peripheral nervous system neoplasm	1.21e-05	8.99e-05	CbGpPWpGaD
Droxidopa—ADRA2A—Signaling Pathways—CASP3—peripheral nervous system neoplasm	1.19e-05	8.9e-05	CbGpPWpGaD
Droxidopa—ADRA1A—Signaling by GPCR—AKT1—peripheral nervous system neoplasm	1.18e-05	8.78e-05	CbGpPWpGaD
Droxidopa—ADRA2C—Signaling Pathways—MYC—peripheral nervous system neoplasm	1.15e-05	8.56e-05	CbGpPWpGaD
Droxidopa—ADRA1B—Signaling Pathways—MYC—peripheral nervous system neoplasm	1.13e-05	8.42e-05	CbGpPWpGaD
Droxidopa—ADRA1D—Signaling Pathways—TP53—peripheral nervous system neoplasm	1.12e-05	8.33e-05	CbGpPWpGaD
Droxidopa—ADRA2A—Signaling by GPCR—AKT1—peripheral nervous system neoplasm	1.09e-05	8.16e-05	CbGpPWpGaD
Droxidopa—ADRA1A—Signaling Pathways—NRAS—peripheral nervous system neoplasm	1.08e-05	8.03e-05	CbGpPWpGaD
Droxidopa—ADRA1D—Signaling Pathways—HRAS—peripheral nervous system neoplasm	1.07e-05	7.97e-05	CbGpPWpGaD
Droxidopa—ADRB1—Signaling Pathways—TP53—peripheral nervous system neoplasm	1.02e-05	7.59e-05	CbGpPWpGaD
Droxidopa—ADRA2B—Signaling Pathways—TP53—peripheral nervous system neoplasm	1.01e-05	7.52e-05	CbGpPWpGaD
Droxidopa—ADRA1A—Signaling Pathways—MYC—peripheral nervous system neoplasm	1e-05	7.48e-05	CbGpPWpGaD
Droxidopa—ADRA2A—Signaling Pathways—NRAS—peripheral nervous system neoplasm	1e-05	7.46e-05	CbGpPWpGaD
Droxidopa—ADRB2—Signaling Pathways—TP53—peripheral nervous system neoplasm	9.97e-06	7.43e-05	CbGpPWpGaD
Droxidopa—ADRB1—Signaling Pathways—HRAS—peripheral nervous system neoplasm	9.74e-06	7.26e-05	CbGpPWpGaD
Droxidopa—ADRA2B—Signaling Pathways—HRAS—peripheral nervous system neoplasm	9.65e-06	7.2e-05	CbGpPWpGaD
Droxidopa—ADRB2—Signaling Pathways—HRAS—peripheral nervous system neoplasm	9.53e-06	7.1e-05	CbGpPWpGaD
Droxidopa—ADRA2C—Metabolism—AKT1—peripheral nervous system neoplasm	9.52e-06	7.1e-05	CbGpPWpGaD
Droxidopa—ADRA1D—Signaling Pathways—AKT1—peripheral nervous system neoplasm	9.44e-06	7.04e-05	CbGpPWpGaD
Droxidopa—ADRA2C—Signaling Pathways—TP53—peripheral nervous system neoplasm	9.43e-06	7.03e-05	CbGpPWpGaD
Droxidopa—ADRA2A—Signaling Pathways—MYC—peripheral nervous system neoplasm	9.33e-06	6.95e-05	CbGpPWpGaD
Droxidopa—ADRA1B—Signaling Pathways—TP53—peripheral nervous system neoplasm	9.28e-06	6.92e-05	CbGpPWpGaD
Droxidopa—ADRA2C—Signaling Pathways—HRAS—peripheral nervous system neoplasm	9.02e-06	6.72e-05	CbGpPWpGaD
Droxidopa—ADRA1B—Signaling Pathways—HRAS—peripheral nervous system neoplasm	8.88e-06	6.62e-05	CbGpPWpGaD
Droxidopa—ADRB1—Signaling Pathways—AKT1—peripheral nervous system neoplasm	8.6e-06	6.41e-05	CbGpPWpGaD
Droxidopa—ADRA2B—Signaling Pathways—AKT1—peripheral nervous system neoplasm	8.52e-06	6.35e-05	CbGpPWpGaD
Droxidopa—ADRB2—Signaling Pathways—AKT1—peripheral nervous system neoplasm	8.42e-06	6.27e-05	CbGpPWpGaD
Droxidopa—ADRA1A—Signaling Pathways—TP53—peripheral nervous system neoplasm	8.24e-06	6.14e-05	CbGpPWpGaD
Droxidopa—ADRA2C—Signaling Pathways—AKT1—peripheral nervous system neoplasm	7.96e-06	5.94e-05	CbGpPWpGaD
Droxidopa—ADRA1A—Signaling Pathways—HRAS—peripheral nervous system neoplasm	7.88e-06	5.88e-05	CbGpPWpGaD
Droxidopa—ADRA1B—Signaling Pathways—AKT1—peripheral nervous system neoplasm	7.84e-06	5.84e-05	CbGpPWpGaD
Droxidopa—ADRA2A—Metabolism—AKT1—peripheral nervous system neoplasm	7.73e-06	5.77e-05	CbGpPWpGaD
Droxidopa—ADRA2A—Signaling Pathways—TP53—peripheral nervous system neoplasm	7.66e-06	5.71e-05	CbGpPWpGaD
Droxidopa—ADRA2A—Signaling Pathways—HRAS—peripheral nervous system neoplasm	7.32e-06	5.46e-05	CbGpPWpGaD
Droxidopa—ADRA1A—Signaling Pathways—AKT1—peripheral nervous system neoplasm	6.96e-06	5.19e-05	CbGpPWpGaD
Droxidopa—ADRA2A—Signaling Pathways—AKT1—peripheral nervous system neoplasm	6.47e-06	4.82e-05	CbGpPWpGaD
